Melody Maarouf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Melody Maarouf has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Vivian Yan Shi
Department of Dermatology University of Washington Seattle Washington USA
17 shared publications - Aleksi J. Hendricks
University of Arizona College of Medicine, Tucson, Arizona, USA
4 shared publications - Jennifer Lin Hsiao
Department of Dermatology University of Southern California Los Angeles California USA
3 shared publications - Jennifer M. Fernandez
Department of Dermatology, University of Nebraska Medical Center, Omaha, NE, USA
3 shared publications A. R. Vaughn
College of Medicine, Drexel University, Philadelphia, Pennsylvania
1 shared publicationA.M. Thompson
University of ArizonaCollege of Medicine Tucson AZ USA
1 shared publication
Latest Publications
- 6 January 2025
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 50 (6) , 1211-1214
Double dose of dupilumab shows efficacy in treatment-resistant bullous pemphigoid
We present the case of an 80-year-old man with multitreatment-resistant immunotherapy-induced bullous pemphigoid (BP) who experienced resolution following treatment with biweekly double-dosed (600 mg subcutaneous) dupilumab, an emerging treatment option for BP. Our findings suggest the potential efficacy of intensified dupilumab dosing in managing immunotherapy-induced BP that is multi-treatment resistant or resistant to standard dupilumab dosing.
- 6 January 2025
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 50 (6) , 1211-1214
Double dose of dupilumab shows efficacy in treatment-resistant bullous pemphigoid
We present the case of an 80-year-old man with multitreatment-resistant immunotherapy-induced bullous pemphigoid (BP) who experienced resolution following treatment with biweekly double-dosed (600 mg subcutaneous) dupilumab, an emerging treatment option for BP. Our findings suggest the potential efficacy of intensified dupilumab dosing in managing immunotherapy-induced BP that is multi-treatment resistant or resistant to standard dupilumab dosing.
- 24 June 2022
- Published by S. Karger AG in Skin Appendage Disorders
- Vol. 8 (6) , 448-453
Relationship Disturbances in Hidradenitis Suppurativa: A Patient Perspective
Introduction: Hidradenitis suppurativa (HS) can significantly impact patients’ relationships. Methods: Using an anonymous electronic survey, we aimed to determine what aspects of sexual relationships are affected by HS discomfort and patients’ reluctance to discuss HS with their partner. Results: Among the 873 participants, 60.9% reported that some aspect of their relationship was affected by HS discomfort, with the greatest being their sexual encounters with spouse (49.1%). Furthermore, 43.0% (320) of participants reported feeling reluctant to discuss HS with their spouse/significant other, with the more common reason being fear of partner seeing boils and scars (84.7%). Multiple aspects of relationships can be affected by HS such as sexual encounters, overall relationship, and finding a relationship. Additionally, several communication barriers are present, such as fear of partner seeing boils and scars, partner thinking they had an infection such as a sexually transmitted disease, and fear of bloody or malodorous drainage, among others. The presence of anogenital pain, Hurley stage, gender, and age significantly affect these findings. Conclusion: Addressing HS-related relationship disturbances should be included in HS management.
- 24 June 2022
- Published by S. Karger AG in Skin Appendage Disorders
- Vol. 8 (6) , 448-453
Relationship Disturbances in Hidradenitis Suppurativa: A Patient Perspective
Introduction: Hidradenitis suppurativa (HS) can significantly impact patients’ relationships. Methods: Using an anonymous electronic survey, we aimed to determine what aspects of sexual relationships are affected by HS discomfort and patients’ reluctance to discuss HS with their partner. Results: Among the 873 participants, 60.9% reported that some aspect of their relationship was affected by HS discomfort, with the greatest being their sexual encounters with spouse (49.1%). Furthermore, 43.0% (320) of participants reported feeling reluctant to discuss HS with their spouse/significant other, with the more common reason being fear of partner seeing boils and scars (84.7%). Multiple aspects of relationships can be affected by HS such as sexual encounters, overall relationship, and finding a relationship. Additionally, several communication barriers are present, such as fear of partner seeing boils and scars, partner thinking they had an infection such as a sexually transmitted disease, and fear of bloody or malodorous drainage, among others. The presence of anogenital pain, Hurley stage, gender, and age significantly affect these findings. Conclusion: Addressing HS-related relationship disturbances should be included in HS management.
- 1 August 2021
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 85 (2) , 499-501
Acne disparities in Native Americans
- 1 August 2021
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 85 (2) , 499-501
Acne disparities in Native Americans
- 27 July 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (4) , E592-E594
Misdiagnoses and barriers to care in hidradenitis suppurativa: A patient survey
- 27 July 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (4) , E592-E594
Misdiagnoses and barriers to care in hidradenitis suppurativa: A patient survey
- 5 March 2021
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 185 (1) , 225-226
Identifying triggers for hidradenitis suppurativa flare: a patient survey
Hidradenitis suppurativa (HS) is a chronic inflammatory dermatosis characterized by painful nodules, abscesses, and sinus tracts in intertriginous areas. There is a paucity of literature on contributors of disease worsening. We aimed to identify common triggers for HS exacerbation from the perspective of patients to improve strategies for avoidance.
- 5 March 2021
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 185 (1) , 225-226
Identifying triggers for hidradenitis suppurativa flare: a patient survey
Hidradenitis suppurativa (HS) is a chronic inflammatory dermatosis characterized by painful nodules, abscesses, and sinus tracts in intertriginous areas. There is a paucity of literature on contributors of disease worsening. We aimed to identify common triggers for HS exacerbation from the perspective of patients to improve strategies for avoidance.
- 29 August 2020
- Published by Wiley in Dermatologic Therapy
- Vol. 33 (6) , e14246
Alleviating and exacerbating foods in hidradenitis suppurativa
Background While dietary triggers have been investigated in acne and other inflammatory follicular dermatoses, there is a paucity of data on diet and HS. We sought to identify exacerbating and alleviating foods in HS patients. Methods An anonymous survey was distributed via HS Facebook support groups and in person at HS specialty clinics. Participants were asked to select all that apply from a list to indicate foods that worsen and make HS better including sweet foods, breads and pasta, red meat, chicken, fish, canned foods, fruits, vegetables, dairy, high‐fat foods, I do not know, and no. Results Only 12.0% (n=89/744) identified alleviating foods while 32.6% (n=237/728) identified HS‐symptom‐exacerbating foods. The most commonly reported exacerbating foods were sweets (67.9%), bread/pasta/rice (51.1%), dairy (50.6%), and high‐fat foods (44.2%). The most commonly reported alleviating foods included vegetables (78.7%), fruit (56.2%), chicken (51.7%), and fish (42.7%). Conclusion Further studies are required to evaluate the mechanistic links between diet and HS. HS patients may benefit from receiving dietary counseling as part of a comprehensive HS management plan.
- 29 August 2020
- Published by Wiley in Dermatologic Therapy
- Vol. 33 (6) , e14246
Alleviating and exacerbating foods in hidradenitis suppurativa
Background While dietary triggers have been investigated in acne and other inflammatory follicular dermatoses, there is a paucity of data on diet and HS. We sought to identify exacerbating and alleviating foods in HS patients. Methods An anonymous survey was distributed via HS Facebook support groups and in person at HS specialty clinics. Participants were asked to select all that apply from a list to indicate foods that worsen and make HS better including sweet foods, breads and pasta, red meat, chicken, fish, canned foods, fruits, vegetables, dairy, high‐fat foods, I do not know, and no. Results Only 12.0% (n=89/744) identified alleviating foods while 32.6% (n=237/728) identified HS‐symptom‐exacerbating foods. The most commonly reported exacerbating foods were sweets (67.9%), bread/pasta/rice (51.1%), dairy (50.6%), and high‐fat foods (44.2%). The most commonly reported alleviating foods included vegetables (78.7%), fruit (56.2%), chicken (51.7%), and fish (42.7%). Conclusion Further studies are required to evaluate the mechanistic links between diet and HS. HS patients may benefit from receiving dietary counseling as part of a comprehensive HS management plan.
- Open Access
- 1 January 2020
- Published by California Digital Library (CDL) in Dermatology Online Journal
- Vol. 26 (7)
Erythrodermic Darier disease associated with metastatic lung adenocarcinoma
We present a patient with erythrodermic Darier disease occurring in temporal association with diagnosis of metastatic lung adenocarcinoma. The patient presented with eroded and crusted keratotic papules and plaques over greater than 90% body surface area with extensive secondary impetiginization. Given a longstanding history of pruritic eruption, this presentation represents a paraneoplastic flare of an underlying genodermatosis. Near total resolution was achieved with chemotherapy and topical corticosteroids.
- 1 January 2020
- Published by California Digital Library (CDL) in Dermatology Online Journal
- Vol. 26 (7)
Open AccessErythrodermic Darier disease associated with metastatic lung adenocarcinoma
We present a patient with erythrodermic Darier disease occurring in temporal association with diagnosis of metastatic lung adenocarcinoma. The patient presented with eroded and crusted keratotic papules and plaques over greater than 90% body surface area with extensive secondary impetiginization. Given a longstanding history of pruritic eruption, this presentation represents a paraneoplastic flare of an underlying genodermatosis. Near total resolution was achieved with chemotherapy and topical corticosteroids.
- 3 April 2019
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 32 (3) , e12890
5‐fluorouracil‐induced erythema and transepidermal water loss associated with complete actinic keratosis resolution
- 3 April 2019
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 32 (3) , e12890
5‐fluorouracil‐induced erythema and transepidermal water loss associated with complete actinic keratosis resolution
- 19 March 2019
- Published by S. Karger AG in Dermatology
- Vol. 235 (3) , 250-252
Augmented Intelligence in Dermatology: Fantasy or Future?
- 19 March 2019
- Published by S. Karger AG in Dermatology
- Vol. 235 (3) , 250-252
Augmented Intelligence in Dermatology: Fantasy or Future?
- 28 January 2019
- Published by Wiley in Dermatologic Therapy
- Vol. 32 (3) , e12840
Current and emerging therapies for hand eczema
Purpose Though hand eczema (HE) and chronic hand eczema (CHE) are common conditions with significant disease burden, they traditionally have had limited treatment options beyond topical and short‐term systemic corticosteroids. We reviewed published and preliminary evidence on the current and emerging topical and systemic therapeutic agents for HE and CHE. The etiologies of various HE subtypes are discussed, and remaining knowledge and practice gaps are highlighted to encourage further investigations. Material and Methods A comprehensive search of ClinicalTrials.gov and PubMed was completed for clinical trials that utilized known and emerging treatment options for HE and CHE. Results Several agents that target IL‐4 and IL‐13 signaling, keratinocyte proliferation, inflammatory cytokine production, bacterial protein synthesis, and inflammatory mediator (TNF‐ α, JAK1, JAK2, JAK3) proliferation are shown to be involved in the pathogenesis of CHE. Systemic agents include dupilumab, alitretinoin, acitretin, cyclosporine, azathioprine, and probiotics. Topical agents include delgocitinib, retapamulin, halometasone/triclosan, calcipotriol/betamethasone, tacrolimus, and pimecrolimus. These modalities have demonstrated varying degrees of clinical efficacy, evaluated by subjective assessments and scoring indexes. Conclusions Targeted therapies are emerging for HE, but options are still limited, partially due to our narrow understanding of this heterogeneous condition. Additional and targeted therapeutic options are needed to match the rising prevalence and burden of HE.
- 28 January 2019
- Published by Wiley in Dermatologic Therapy
- Vol. 32 (3) , e12840
Current and emerging therapies for hand eczema
Purpose Though hand eczema (HE) and chronic hand eczema (CHE) are common conditions with significant disease burden, they traditionally have had limited treatment options beyond topical and short‐term systemic corticosteroids. We reviewed published and preliminary evidence on the current and emerging topical and systemic therapeutic agents for HE and CHE. The etiologies of various HE subtypes are discussed, and remaining knowledge and practice gaps are highlighted to encourage further investigations. Material and Methods A comprehensive search of ClinicalTrials.gov and PubMed was completed for clinical trials that utilized known and emerging treatment options for HE and CHE. Results Several agents that target IL‐4 and IL‐13 signaling, keratinocyte proliferation, inflammatory cytokine production, bacterial protein synthesis, and inflammatory mediator (TNF‐ α, JAK1, JAK2, JAK3) proliferation are shown to be involved in the pathogenesis of CHE. Systemic agents include dupilumab, alitretinoin, acitretin, cyclosporine, azathioprine, and probiotics. Topical agents include delgocitinib, retapamulin, halometasone/triclosan, calcipotriol/betamethasone, tacrolimus, and pimecrolimus. These modalities have demonstrated varying degrees of clinical efficacy, evaluated by subjective assessments and scoring indexes. Conclusions Targeted therapies are emerging for HE, but options are still limited, partially due to our narrow understanding of this heterogeneous condition. Additional and targeted therapeutic options are needed to match the rising prevalence and burden of HE.